You are here: Industry Insights > Market News > NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Borosilicate Glass Reactor

1-(3-METHYL-1-PHENYL-5-PYRAZOLYL)PIPERAZINE

2 '- Deoxycytidine

2 '- Deoxyuridine

Steviol Glycosides Reb I

Steviol Glycosides Reb E

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

chinadailyAugust 21, 2019

Tag: NMPA , Announcement , Drug Standards

Favorites

To promote the consistency evaluation of the quality and efficacy of generic drugs, and clarify the relationship between the registration standards of generic drugs and the national drug standards such as the Pharmacopoeia of the People's Republic of China, on August 2, 2019, NMPA issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs.

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content,

please email: Julia.Zhang@ubmsinoexpo.com to delete.

Previous:Nabriva’s bacterial pneumonia drug gets US regulatory approval

Next:NMPA Issued the Notice on Expanding the Pilot of the Medical Device Registrant System

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may like
More>>

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

NMPA Issued the Announcement on Issues Pertaining to the Implementation of Drug Standards in the Consistency Evaluation of the Quality and Efficacy of Generic Drugs

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may likeMore>>

You may like
More>>